Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia

PHASE3TerminatedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

December 31, 2009

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Arsenic trioxide

Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.

DRUG

Low-dose cytarabine alone

Cytarabine will be administered at a dose of 10 mg/m\^2 subcutaneously (sc) twice a day (bid).

Trial Locations (12)

10011

St. Vincent's Comprehensive Cancer Center, New York

10021

Weill Medical College of Cornell University, New York

14263

Roswell Park Cancer Institute, Buffalo

27834

Brody School of Medicine, Greenville

29425

Medical University of South Carolina, Charleston

46202

Indiana Oncology Hematology Consultants, Indianapolis

60612

University of Illinois, Chicago

73104

University of Oklahoma, Oklahoma City

78229

UT Health Science Center, San Antonio

90033

USC / Norris Cancer Hospital, Los Angeles

90095

UCLA Medical Center, Los Angeles

M5G2M9

Princess Margaret Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY